Gemcitabine plus oxaliplatin with or without rituximab: treatment for elderly patients with B-cell lymphoma

VernacularTitle:吉西他滨联合奥沙利铂方案加或不加利妥昔抗治疗老年人B细胞淋巴瘤11例
Author: Wenyi SHEN ; Peng LIU ; Jianyong LI
Publication Type:Journal Article
Keywords: Lymphoma,B-cell; Gemcitabine,oxaliplatin
From: Journal of Leukemia & Lymphoma 2012;21(3):159-162
CountryChina
Language:Chinese
Abstract: Objective To study the efficacy, safety and tolerance of the therapeutic schedule of GemOx±R regimen suitable for elderly patients with B-cell lymphoma. Methods 11 elderly patients with B-cell lymphoma were enrolled in this study, which were diagnosed by biopsy. All the patients were treated according the GemOx ± R therapeutic schedule as described: rituximab (375 mg/m2 on day 0),gemcitabine (1000 mg/m2 on day 1),oxaliplatin (100 mg/m2 on day 1).Treatment response,therapy related toxic and sideeffect were assessed after inductive and consolidated treatment. Results The median age of 11 patients were 72.18 years(range 55-83 years).The overall response rate(ORR) after inductive treatment was 90 ％(9/10).The ORR of 4 DLBCL patients using GemOx+R as initial treatment was 100 ％. GemOx regimen were used for 4 refractory/relapse patients,and 3/4 patients got PR after inductive treatment.No patient got dose adjustment.The hematological toxicity was controllable and nobody got renal function impairment. Conclusions The GemOx ± R regimen is feasible,tolerable,effective for elderly patients with B-cell lymphoma.